Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GC021109 in Healthy Volunteers
NCT02254369Phase 1Completed
- Sponsor
- GliaCure, Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GC021109 in Alzheimer's disease (AD) (10 cohorts), sponsored by GliaCure, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2014; status: completed.
02
Drugs
GC021109
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02254369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254369.